Inhibrx Biosciences Inc. (INBX) Cash Flow Statement Analysis - Operating Cash Flow, CapEx & Free Cash Flow - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Inhibrx Biosciences Inc.

    NASDAQ: INBX · Real-Time Price · USD
    28.18
    0.46 (1.66%)
    At close: Sep 05, 2025, 3:59 PM
    28.18
    0.00%
    After-hours: Sep 05, 2025, 04:33 PM EDT

    Inhibrx Biosciences Cash Flow Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Net Income
    		 1.69B -239.73M -145.23M -81.77M
    Depreciation & Amortization
    		 2.29M 1.19M 1.23M 1.2M
    Stock-Based Compensation
    		 58.52M 24.85M 20.45M 15.05M
    Other Working Capital
    		 33.77M 13.76M 3.74M -1.67M
    Other Non-Cash Items
    		 -1.99B 5.03M 5.09M 2.73M
    Deferred Income Tax
    		 n/a n/a n/a -9K
    Change in Working Capital
    		 52.05M 15.35M 3.16M -17.52M
    Operating Cash Flow
    		 -194.41M -193.31M -115.3M -80.32M
    Capital Expenditures
    		 -2.6M -4.59M -686K -864K
    Cash Acquisitions
    		 n/a n/a n/a 55K
    Purchase of Investments
    		 n/a n/a n/a n/a
    Sales Maturities Of Investments
    		 n/a n/a n/a n/a
    Other Investing Acitivies
    		 n/a n/a n/a n/a
    Investing Cash Flow
    		 -2.6M -4.59M -686K -809K
    Debt Repayment
    		 n/a n/a n/a n/a
    Common Stock Repurchased
    		 n/a n/a n/a n/a
    Dividend Paid
    		 n/a n/a n/a n/a
    Other Financial Acitivies
    		 n/a n/a 128.81M 83.77M
    Financial Cash Flow
    		 71.68M 201.96M 258.55M 83.77M
    Net Cash Flow
    		 -125.33M 4.06M 142.56M 2.64M
    Free Cash Flow
    		 -197.01M -197.9M -115.99M -81.19M

    Add to Watchlist